-
1
-
-
78049423379
-
Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer
-
Li F, Sun X, Sun N et al.: Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 33, 489-494 (2010).
-
(2010)
Am. J. Clin. Oncol.
, vol.33
, pp. 489-494
-
-
Li, F.1
Sun, X.2
Sun, N.3
-
2
-
-
77956188702
-
The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis
-
Chen S, Zhang J, Wang R et al.: The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70, 63-70 (2010).
-
(2010)
Lung Cancer
, vol.70
, pp. 63-70
-
-
Chen, S.1
Zhang, J.2
Wang, R.3
-
3
-
-
0038350391
-
Genetic testing for chemotherapy in non-small cell lung cancer
-
DOI 10.1016/S0169-5002(03)00151-X
-
Rosell R, Taron M, Alberola V et al.: Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41, S97-S102 (2003). (Pubitemid 36819001)
-
(2003)
Lung Cancer
, vol.41
, Issue.SUPPL. 1
-
-
Rosell, R.1
Taron, M.2
Alberola, V.3
Massuti, B.4
Felip, E.5
-
4
-
-
79955525769
-
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis
-
Epub ahead of print
-
Yin M, Yan J, Voutsina A et al.: No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer (2010) (Epub ahead of print).
-
(2010)
Lung Cancer
-
-
Yin, M.1
Yan, J.2
Voutsina, A.3
-
5
-
-
0011511768
-
Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs
-
Alison MR (Ed.). Nature Publishing Group, London, UK
-
Siddik ZH: Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: The Cancer Handbook. Alison MR (Ed.). Nature Publishing Group, London, UK, 1295-1313 (2002).
-
(2002)
The Cancer Handbook
, pp. 1295-1313
-
-
Zh, S.1
-
6
-
-
78650944117
-
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine
-
Viñolas N, Provencio M, Reguart N et al.: Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71, 191-198 (2011).
-
(2011)
Lung Cancer
, vol.71
, pp. 191-198
-
-
Viñolas, N.1
Provencio, M.2
Reguart, N.3
-
7
-
-
0346238665
-
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
-
DOI 10.1056/NEJMoa031644
-
Arriagada R, Bergman B, Dunant A et al.; The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351-360 (2004). (Pubitemid 38101630)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.4
, pp. 351-360
-
-
Arriagada, R.1
Bergman, B.2
Dunant, A.3
Le Chevalier, T.4
Pignon, J.-P.5
Vansteenkiste, J.6
-
8
-
-
0036732039
-
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells
-
Furuta T, Ueda T, Aune G et al.: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62, 4899-4902 (2002). (Pubitemid 34984411)
-
(2002)
Cancer Research
, vol.62
, Issue.17
, pp. 4899-4902
-
-
Furuta, T.1
Ueda, T.2
Aune, G.3
Sarasin, A.4
Kraemer, K.H.5
Pommier, Y.6
-
10
-
-
0032478718
-
DNA structural elements required for ERCC1-XPF endonuclease activity
-
DOI 10.1074/jbc.273.14.7835
-
de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH: DNA structural elements required for ERCC1-XPF endonuclease activity. J. Biol. Chem. 273, 7835-7842 (1998). (Pubitemid 28168827)
-
(1998)
Journal of Biological Chemistry
, vol.273
, Issue.14
, pp. 7835-7842
-
-
De Laat, W.L.1
Appeldoorn, E.2
Jaspers, N.G.J.3
Hoeijmakers, J.H.J.4
-
11
-
-
33748435058
-
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
-
DOI 10.1056/NEJMoa060570
-
Olaussen KA, Dunant A, Fouret P et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991(2006). (Pubitemid 44343542)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.10
, pp. 983-991
-
-
Olaussen, K.A.1
Dunant, A.2
Fouret, P.3
Brambilla, E.4
Andre, F.5
Haddad, V.6
Taranchon, E.7
Filipits, M.8
Pirker, R.9
Popper, H.H.10
Stahel, R.11
Sabatier, L.12
Pignon, J.-P.13
Tursz, T.14
Le Chevalier, T.15
Soria, J.-C.16
-
13
-
-
0031224917
-
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues
-
DOI 10.1016/S1383-5726(97)00004-6, PII S1383572697000046
-
Yu JJ, Mu C, Lee KB et al.: A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382, 13-20 (1997). (Pubitemid 28376643)
-
(1997)
Mutation Research - Mutation Research Genomics
, vol.382
, Issue.1-2
, pp. 13-20
-
-
Yu, J.J.1
Mu, C.2
Lee, K.B.3
Okamoto, A.4
Reed, E.L.5
Bostick-Bruton, F.6
Mitchell, K.C.7
Reed, E.8
-
14
-
-
0033848268
-
Association of an ERCC1 polymorphism with adult-onset glioma
-
Chen P, Wiencke J, Aldape K et al.: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 9, 843-847 (2000). (Pubitemid 30660059)
-
(2000)
Cancer Epidemiology Biomarkers and Prevention
, vol.9
, Issue.8
, pp. 843-847
-
-
Chen, P.1
Wiencke, J.2
Aldape, K.3
Kesler-Diaz, A.4
Miike, R.5
Kelsey, K.6
Lee, M.7
Liu, J.8
Wrensch, M.9
-
15
-
-
36849044583
-
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy
-
DOI 10.1200/JCO.2007.11.8547
-
Smith S, Su D, Rigault de la Longrais IA et al.: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25, 5172-5179 (2007). (Pubitemid 350232247)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5172-5179
-
-
Smith, S.1
Su, D.2
Rigault De La Longrais, I.A.3
Schwartz, P.4
Puopolo, M.5
Rutherford, T.J.6
Mor, G.7
Yu, H.8
Katsaros, D.9
-
16
-
-
77957696698
-
Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients
-
Zhou C, Ren S, Zhou S et al.: Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 40, 954-960 (2010).
-
(2010)
Jpn. J. Clin. Oncol.
, vol.40
, pp. 954-960
-
-
Zhou, C.1
Ren, S.2
Zhou, S.3
-
17
-
-
65349117547
-
DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer
-
Kalikaki A, Kanaki M, Vassalou H et al.: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 10, 118-123 (2009).
-
(2009)
Clin. Lung Cancer
, vol.10
, pp. 118-123
-
-
Kalikaki, A.1
Kanaki, M.2
Vassalou, H.3
-
18
-
-
79952251471
-
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis
-
Wei SZ, Zhan P, Shi MQ et al.: Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28(1), 315-321 (2011).
-
(2011)
Med. Oncol.
, vol.28
, Issue.1
, pp. 315-321
-
-
Wei, S.Z.1
Zhan, P.2
Shi, M.Q.3
-
19
-
-
4444256594
-
Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer
-
DOI 10.1093/annonc/mdh319
-
Isla D, Sarries C, Rosell R et al.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203 (2004). (Pubitemid 39199306)
-
(2004)
Annals of Oncology
, vol.15
, Issue.8
, pp. 1194-1203
-
-
Isla, D.1
Sarries, C.2
Rosell, R.3
Alonso, G.4
Domine, M.5
Taron, M.6
Lopez-Vivanco, G.7
Camps, C.8
Botia, M.9
Nunez, L.10
Sanchez-Ronco, M.11
Sanchez, J.J.12
Lopez-Brea, M.13
Barneto, I.14
Paredes, A.15
Medina, B.16
Artal, A.17
Lianes, P.18
-
20
-
-
71549134934
-
Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients
-
Takenaka T, Yano T, Kiyohara C et al.: Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67, 101-107 (2010).
-
(2010)
Lung Cancer
, vol.67
, pp. 101-107
-
-
Takenaka, T.1
Yano, T.2
Kiyohara, C.3
-
21
-
-
41549095093
-
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
-
DOI 10.1158/1078-0432.CCR-07-1364
-
Tibaldi C, Giovannetti E, Vasile E et al.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14, 1797-1803 (2008). (Pubitemid 351469466)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.6
, pp. 1797-1803
-
-
Tibaldi, C.1
Giovannetti, E.2
Vasile, E.3
Mey, V.4
Laan, A.C.5
Nannizzi, S.6
Di Marsico, R.7
Antonuzzo, A.8
Orlandini, C.9
Ricciardi, S.10
Del Tacca, M.11
Peters, G.J.12
Falcone, A.13
Danesi, R.14
|